U.K. Biosimulation Market Size & Outlook, 2026-2033
Global Market
Related Markets
UK biosimulation market highlights
- The UK biosimulation market generated a revenue of USD 249.7 million in 2025 and is expected to reach USD 852.0 million by 2033.
- The UK market is expected to grow at a CAGR of 16.6% from 2026 to 2033.
- In terms of segment, software was the largest revenue generating product in 2025.
- Services is the most lucrative product segment registering the fastest growth during the forecast period.
Biosimulation market data book summary
| Market revenue in 2025 | USD 249.7 million |
| Market revenue in 2033 | USD 852.0 million |
| Growth rate | 16.6% (CAGR from 2026 to 2033) |
| Largest segment | Software |
| Fastest growing segment | Services |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Software, Services |
| Key market players worldwide | Certara Inc Ordinary Shares, Dassault Systemes SE, Avantium NV, Simulations Plus Inc, Schrodinger Inc Ordinary Shares, Chemical Computing Group, Physiomics, Rosa & Co, Genedata AG, Instem, Yokogawa Electric Corp., Immunetrics |
Other key industry trends
- In terms of revenue, UK accounted for 6.0% of the global biosimulation market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany biosimulation market is projected to lead the regional market in terms of revenue in 2033.
- France is the fastest growing regional market in Europe and is projected to reach USD 618.6 million by 2033.
Increasing research incorporating biosimulation as a drug development tool is expected to drive the market growth in the country. The key purpose is to integrate multiple areas such as pathology, ethnography, computer graphics, & medical imaging and evaluate the chances of success that fulfills the needs of both health services and individual researchers.
According to NIHR, there has been a small increase in the number of clinical trials that have been conducted in the country. There have been significant improvements in regulatory framework for attracting industry players. Increasing number of clinical research activities and improvements in regulatory framework are expected to boost the market growth during the forecast period.
No credit card required*
Publish Date: May 29, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Biosimulation Market Scope
Biosimulation Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Certara Inc Ordinary Shares | View profile | 1,391 | 100 Overlook Center, Suite 101, Princeton, NJ, United States, 08540 | www.certara.com |
| Dassault Systemes SE | View profile | 23,811 | 10, Rue Marcel Dassault, Velizy-Villacoublay, France, 78140 | www.3ds.com |
| Avantium NV | View profile | 249 | Zekeringstraat 29-31, Amsterdam, Netherlands, 1014 BV | www.avantium.com |
| Simulations Plus Inc | View profile | 197 | 42505 Tenth Street West, Lancaster, CA, United States, 93534-7059 | www.simulations-plus.com |
| Schrodinger Inc Ordinary Shares | View profile | 787 | 1540 Broadway, 24th Floor, New York, NY, United States, 10036 | www.schrodinger.com |
| Chemical Computing Group | View profile | 11-50 | Montreal, Quebec, Canada, North America | www.chemcomp.com |
| Physiomics | View profile | 11-50 | Oxford, Oxfordshire, United Kingdom, Europe | www.physiomics-plc.com/ |
| Rosa & Co | View profile | 11-50 | San Carlos, California, United States, North America | www.rosaandco.com |
| Genedata AG | View profile | 51-100 | Basel, Basel-Stadt, Switzerland, Europe | www.genedata.com/ |
| Instem | View profile | 51-100 | Conshohocken, Pennsylvania, United States, North America | www.instem.com |
U.K. Biosimulation Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biosimulation Market Outlook will help companies and investors design strategic landscapes.
Software was the largest segment with a revenue share of 67.24% in 2025.
Horizon Databook has segmented the U.K. biosimulation market based on software, services covering the revenue growth of each sub-segment from 2021 to 2033.
Increasing research incorporating biosimulation as a drug development tool is expected to drive the market growth in the country. The key purpose is to integrate multiple areas such as pathology, ethnography, computer graphics, & medical imaging and evaluate the chances of success that fulfills the needs of both health services and individual researchers.
According to NIHR, there has been a small increase in the number of clinical trials that have been conducted in the country. There have been significant improvements in regulatory framework for attracting industry players. Increasing number of clinical research activities and improvements in regulatory framework are expected to boost the market growth during the forecast period.
- U.K. Biosimulation Market Product Outlook (Revenue, USD Million , 2021-2033)
- Software
- Services
Reasons to subscribe to Biosimulation Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Biosimulation Market Outlook databook
- Our clientele includes a mix of Biosimulation Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.K. Biosimulation Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.K. Biosimulation Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.K. Biosimulation Market, 2021-2033 (US$M)
UK Product - Biosimulation Market Statistics, 2025 - 2033 (US$M)
